If the mountain won't come to Mohammed, then Mohammed must go to the mountain: Decentralisation of hepatitis C care for people who use drugs.
作者信息
Von den Hoff Daan W, Berden Floor A C, Schellekens Arnt F A
机构信息
Department of Gastroenterology and Hepatology, Radboud university medical centre, Nijmegen, the Netherlands.
Department of Psychiatry, Radboud university medical centre, Nijmegen, The Netherlands.
出版信息
United European Gastroenterol J. 2021 Dec;9(10):1101-1102. doi: 10.1002/ueg2.12167. Epub 2021 Oct 22.
Abstract
摘要
相似文献
1
If the mountain won't come to Mohammed, then Mohammed must go to the mountain: Decentralisation of hepatitis C care for people who use drugs.
United European Gastroenterol J. 2021 Dec;9(10):1101-1102. doi: 10.1002/ueg2.12167. Epub 2021 Oct 22.
2
If Mohammed won't come to the mountain, the mountain must go to Mohammed.
Age Ageing. 2011 May;40(3):290-2. doi: 10.1093/ageing/afr035. Epub 2011 Mar 31.
3
Decentralisation of hepatitis C virus care into community settings: A key approach on the path to elimination.
Liver Int. 2022 Jun;42(6):1222-1224. doi: 10.1111/liv.15229.
4
To Eliminate Hepatitis C in People Who Inject Drugs, Stop Ignoring Drug-user Health.
Clin Infect Dis. 2021 Jul 1;73(1):e119-e121. doi: 10.1093/cid/ciaa607.
5
Hepatitis C: the virus that won't go away.
Aust Nurs J. 1994 Jul;2(1):32-3.
6
Decentralisation, integration, and task-shifting: tools to accelerate the elimination of hepatitis C.
Lancet Glob Health. 2021 Apr;9(4):e375-e376. doi: 10.1016/S2214-109X(21)00055-3. Epub 2021 Feb 24.
7
Creating an environment for equitable access to direct-acting antiviral therapy for people who inject drugs with hepatitis C.
Liver Int. 2020 Oct;40(10):2353-2355. doi: 10.1111/liv.14661.
8
Hepatitis C and Stimulant Use Disorder: Challenges and Opportunities.
Clin Infect Dis. 2020 Dec 31;71(11):3009. doi: 10.1093/cid/ciaa249.
9
Many eligible federal inmates won't get new hepatitis treatment.
CMAJ. 2016 May 17;188(8):E132. doi: 10.1503/cmaj.109-5252. Epub 2016 Mar 29.
10
It's Not Them, It's Us: Hepatitis C Reinfection Following Successful Treatment Among People Who Inject Drugs.
Clin Infect Dis. 2021 Apr 26;72(8):1401-1403. doi: 10.1093/cid/ciaa258.
引用本文的文献
1
Implementation of a decentralized hepatitis C care pathway for people who use drugs in Dutch addiction care. Study protocol for the Hepatitis C: chain of addiction care (CAC) project.
Addict Sci Clin Pract. 2022 Nov 30;17(1):67. doi: 10.1186/s13722-022-00350-1.
本文引用的文献
1
Increased Hepatitis C virus screening, diagnosis and linkage to care rates among people who use drugs through a patient-centered program from Italy.
United European Gastroenterol J. 2021 Dec;9(10):1109-1118. doi: 10.1002/ueg2.12156. Epub 2021 Oct 26.
2
Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis.
Lancet Glob Health. 2021 Apr;9(4):e431-e445. doi: 10.1016/S2214-109X(20)30505-2. Epub 2021 Feb 24.
3
Loss to follow-up in the hepatitis C care cascade: A substantial problem but opportunity for micro-elimination.
J Viral Hepat. 2020 Dec;27(12):1270-1283. doi: 10.1111/jvh.13399. Epub 2020 Sep 22.
4
EASL recommendations on treatment of hepatitis C: Final update of the series.
J Hepatol. 2020 Nov;73(5):1170-1218. doi: 10.1016/j.jhep.2020.08.018. Epub 2020 Sep 15.
5
Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.
Hepatology. 2020 Feb;71(2):686-721. doi: 10.1002/hep.31060.
6
Hepatitis C virus therapy in advanced liver disease: Outcomes and challenges.
United European Gastroenterol J. 2019 Jun;7(5):642-650. doi: 10.1177/2050640619840149. Epub 2019 Mar 21.
7
The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions.
United European Gastroenterol J. 2017 Aug;5(5):648-657. doi: 10.1177/2050640616678151. Epub 2016 Nov 4.
Zotero 插件